Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4 Suppl
|
| pubmed:dateCreated |
1995-9-1
|
| pubmed:abstractText |
The purpose of this study was to compare dose-related effects on cortical bone and lean body mass following subcutaneous administration of rhIGF-I alone, or bound to an equimolar amount of rhIGFBP-3 to adult Ovx rats. At the age of 16 weeks, rats were ovariectomized or sham-operated and were allowed 8 weeks to develop osteopenia. After being divided into control (saline treated) or treatment groups, rats were injected daily during an 8-week period with 0.9 and 2.6 mg/kg of rhIGF-I, or with 0.9, 2.6, and 7.5 mg/kg of rhIGF-I bound to rhIGFBP-3. Fluorescent bone markers were given 9 and 2 days prior to necropsy. Body weights and lean body mass were monitored throughout the experiment. Cortical bone histomorphometry was performed on tibial cross-sections at the tibiofibular junction, and endochondral bone growth was measured at the distal femoral metaphysis. All rats treated with rhIGF-I or the rhIGF-I/IGFBP-3 complex had increased body weights, corresponding to a dose-dependent increase in lean body mass. Endochondral growth was slightly increased in all experimental groups, but was not dose-dependent. A dramatic increase in periosteal, modeling-dependent formation, coupled with decreased or unchanged resorption on the endocortical envelope resulted in a dose-dependent increase in cortical thickness and cross-sectional area in groups treated with the complex of rhIGF-I/IGFBP-3. This complex appeared to be more effective in promoting positive musculoskeletal changes than rhIGF-I alone.(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Carrier Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Growth Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin-Like Growth Factor Binding...,
http://linkedlifedata.com/resource/pubmed/chemical/Insulin-Like Growth Factor I,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Somatomedins
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
8756-3282
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
16
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
263S-269S
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:7542899-Absorptiometry, Photon,
pubmed-meshheading:7542899-Animals,
pubmed-meshheading:7542899-Body Weight,
pubmed-meshheading:7542899-Bone Density,
pubmed-meshheading:7542899-Bone Development,
pubmed-meshheading:7542899-Bone Diseases, Metabolic,
pubmed-meshheading:7542899-Bone Resorption,
pubmed-meshheading:7542899-Carrier Proteins,
pubmed-meshheading:7542899-Disease Models, Animal,
pubmed-meshheading:7542899-Dose-Response Relationship, Drug,
pubmed-meshheading:7542899-Female,
pubmed-meshheading:7542899-Growth Inhibitors,
pubmed-meshheading:7542899-Insulin-Like Growth Factor Binding Proteins,
pubmed-meshheading:7542899-Insulin-Like Growth Factor I,
pubmed-meshheading:7542899-Muscle, Skeletal,
pubmed-meshheading:7542899-Ovariectomy,
pubmed-meshheading:7542899-Rats,
pubmed-meshheading:7542899-Rats, Sprague-Dawley,
pubmed-meshheading:7542899-Recombinant Proteins,
pubmed-meshheading:7542899-Somatomedins,
pubmed-meshheading:7542899-Tibia
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Systemic administration of rhIGF-I or rhIGF-I/IGFBP-3 increases cortical bone and lean body mass in ovariectomized rats.
|
| pubmed:affiliation |
Department of Preclinical Safety and Efficacy, Celtrix Pharmaceuticals, Santa Clara, CA 95054, USA.
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|